尔康制药：控股股东拟减持公司不超2.04%股份

Core Viewpoint - The controlling shareholder of Erkang Pharmaceutical, Shuai Fangwen, plans to reduce his stake in the company by up to 42 million shares, representing 2.04% of the total share capital, within three months after 15 trading days [1] Group 1 - The controlling shareholder holds 41.38% of the company's shares [1] - The planned reduction will occur through centralized bidding or block trading methods [1] - The maximum number of shares to be sold is specified as 42 million [1]